Professor Robert Seamans is interviewed about Purdue Pharma's shift away from OxyContin
— June 24, 2018
Excerpt from the Stamford Advocate -- "Moving away from opioids is 'definitely a risk, but it seems like a risk worth taking,' said Robert Seamans, an associate professor of management and organizations at New York University. 'To a certain extent, it seems like these types of sharp turns in strategy work better when private companies are making them. And since the CEO comes from the R&D side of the business, it sounds like they have the right person in place, now they have decided to pursue R&D instead of sales.'"